Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development...
Guardado en:
Autores principales: | Elisabeth von Guggenberg, Petra Kolenc, Christof Rottenburger, Renata Mikołajczak, Alicja Hubalewska-Dydejczyk |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/39929c74eb0f41469615cdf0f02b4031 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Cholecystokinin Type 2 Receptor, a Pharmacological Target for Pain Management
por: Amandine Bernard, et al.
Publicado: (2021) -
Altered Gabab Receptor Thermoregulatory Function in Rats with Diet-Induced Obesity
por: Hristov M., et al.
Publicado: (2019) -
Ancient role of sulfakinin/cholecystokinin-type signalling in inhibitory regulation of feeding processes revealed in an echinoderm
por: Ana B Tinoco, et al.
Publicado: (2021) -
The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress
por: Chow M, et al.
Publicado: (2016) -
The entorhinal cortex modulates trace fear memory formation and neuroplasticity in the mouse lateral amygdala via cholecystokinin
por: Hemin Feng, et al.
Publicado: (2021)